BioLineRx (BLRX) Competitors $4.00 +0.10 (+2.56%) Closing price 10/3/2025 03:57 PM EasternExtended Trading$3.80 -0.20 (-5.10%) As of 10/3/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLRX vs. GANX, OSTX, ANL, ELYM, INKT, QNTM, ZIVO, CVM, ALGS, and RLMDShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Gain Therapeutics (GANX), OS Therapies (OSTX), Adlai Nortye (ANL), Eliem Therapeutics (ELYM), MiNK Therapeutics (INKT), Quantum Biopharma (QNTM), ZIVO Bioscience (ZIVO), CEL-SCI (CVM), Aligos Therapeutics (ALGS), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. Its Competitors Gain Therapeutics OS Therapies Adlai Nortye Eliem Therapeutics MiNK Therapeutics Quantum Biopharma ZIVO Bioscience CEL-SCI Aligos Therapeutics Relmada Therapeutics Gain Therapeutics (NASDAQ:GANX) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment. Do analysts prefer GANX or BLRX? Gain Therapeutics presently has a consensus price target of $8.00, indicating a potential upside of 316.67%. BioLineRx has a consensus price target of $26.00, indicating a potential upside of 550.00%. Given BioLineRx's higher possible upside, analysts clearly believe BioLineRx is more favorable than Gain Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Is GANX or BLRX more profitable? Gain Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -45.34%. BioLineRx's return on equity of -49.74% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gain TherapeuticsN/A -289.10% -155.11% BioLineRx -45.34%-49.74%-17.54% Do insiders & institutionals believe in GANX or BLRX? 12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 7.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, GANX or BLRX? Gain Therapeutics has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Which has better valuation and earnings, GANX or BLRX? BioLineRx has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGain Therapeutics$50K1,380.48-$20.41M-$0.63-3.05BioLineRx$28.94M0.59-$9.22M-$8.80-0.45 Does the media refer more to GANX or BLRX? In the previous week, BioLineRx had 3 more articles in the media than Gain Therapeutics. MarketBeat recorded 5 mentions for BioLineRx and 2 mentions for Gain Therapeutics. BioLineRx's average media sentiment score of 0.26 beat Gain Therapeutics' score of -0.50 indicating that BioLineRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative BioLineRx 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBioLineRx beats Gain Therapeutics on 10 of the 17 factors compared between the two stocks. Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.05M$2.63B$6.14B$10.58BDividend YieldN/A56.38%5.67%4.69%P/E Ratio-0.4524.2278.0526.70Price / Sales0.59726.66605.13131.81Price / CashN/A172.1237.9061.31Price / Book0.995.3412.556.55Net Income-$9.22M$32.92M$3.31B$277.50M7 Day Performance4.17%3.90%4.28%2.42%1 Month Performance8.99%8.79%6.90%8.63%1 Year Performance-78.26%-3.79%70.54%31.60% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx2.9162 of 5 stars$4.00+2.6%$26.00+550.0%-78.3%$17.05M$28.94M-0.4540GANXGain Therapeutics2.3732 of 5 stars$1.81+1.1%$8.00+342.0%+5.5%$64.35M$50K-2.8720Positive NewsShort Interest ↑OSTXOS Therapies3.0529 of 5 stars$2.01-2.0%$18.00+795.5%-38.4%$63.61MN/A-2.54N/AAnalyst ForecastANLAdlai Nortye1.9562 of 5 stars$1.77+2.9%$9.00+408.5%-10.9%$63.47M$5M0.00127News CoveragePositive NewsShort Interest ↓Gap DownELYMEliem TherapeuticsN/A$2.13+1.4%N/A-61.2%$63.37MN/A-4.029INKTMiNK Therapeutics2.6157 of 5 stars$13.70-1.9%$37.50+173.7%+109.5%$63.14MN/A-4.7630Gap DownQNTMQuantum Biopharma0.4999 of 5 stars$16.19-0.8%N/A+301.1%$62.28MN/A-1.15N/ANews CoverageGap UpZIVOZIVO Bioscience0.1339 of 5 stars$15.99+15.0%N/A-37.4%$61.03M$15.85K-3.2810Gap UpCVMCEL-SCI1.3816 of 5 stars$8.82-1.5%N/A-67.7%$60.70MN/A-18.3743News CoveragePositive NewsALGSAligos Therapeutics3.9817 of 5 stars$9.62-1.7%$50.00+419.8%+23.4%$60.22M$3.94M-0.4990RLMDRelmada Therapeutics2.5272 of 5 stars$1.88+3.9%$1.00-46.8%-33.3%$60.08MN/A-0.8510Gap Up Related Companies and Tools Related Companies GANX Competitors OSTX Competitors ANL Competitors ELYM Competitors INKT Competitors QNTM Competitors ZIVO Competitors CVM Competitors ALGS Competitors RLMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLRX) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
